Mineralocorticoid receptor antagonists: emerging roles in cardiovascular medicine
John W FunderPrince Henry's Institute, Clayton, Victoria, AustraliaAbstract: Spironolactone was first developed over 50 years ago as a potent mineralocorticoid receptor (MR) antagonist with undesirable side effects; it was followed a decade ago by eplerenone, which is less potent but much mo...
Na minha lista:
| Autor principal: | |
|---|---|
| Formato: | Livro |
| Publicado em: |
Dove Medical Press,
2013-10-01T00:00:00Z.
|
| Assuntos: | |
| Acesso em linha: | Connect to this object online. |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|
Internet
Connect to this object online.3rd Floor Main Library
| Área/Cota: |
A1234.567 |
|---|---|
| Cód. Barras: 1 | Disponível |